![]() |
Market Research Report
Herpes Market to 2018 - Genericization Compels Competitors Seeking Differentiation to Adopt Novel Drug Delivery Technologies |
||||||
Published by | GBI Research | Product code | 235093 | ||||
Published | Content info | 72 Pages ![]() |
|||||
Price |
Not Available
|
Herpes Market to 2018 - Genericization Compels Competitors Seeking Differentiation to Adopt Novel Drug Delivery Technologies | ||
Published: April 1, 2012 | Content info: 72 Pages |
|
This publication has been discontinued on February 2, 2017.
GBI Research's report "Herpes Market to 2018 - Genericization Compels Competitors Seeking Differentiation to Adopt Novel Drug Delivery Technologies" finds that the global herpes market is an attractive one, and is expected to witness growth during the forecast period and to provide good opportunities for investors. The expected high growth is attributed to increasing awareness regarding herpes infections and a growth in the diseased population. Many promising therapies, especially for Cytomegalovirus (CMV) infections, are expected to launch during the forecast period. The market is currently generic in nature, with few first-in-class molecules. The current therapies provide only symptomatic treatment of infections, meaning that infection can lay dormant in patients, recurring in the future. This is unmet need of the market, which needs to be resolved.
The value of the global herpes market (herpes simplex, herpes zoster and Cytomegalovirus infections) is estimated to have been approximately $4.2 billion in 2010, and this figure is expected to grow at a CAGR of 10.1% to reach $9.1 billion by 2018. The market has limited scope for growth due to the heavy presence of generic products and the lack of innovation in the pipeline products. The current treatment options serve the market's needs, providing symptomatic treatment for herpes simplex and herpes zoster infections. There is current unmet need in the market for safer therapeutics, particularly for CMV infections. There are nine molecules in Phase III of clinical development for various herpes infections. The diseased population is expected to reach approximately 158.6 million by 2018, driven by immunosuppressed patients and transplant recipients.
GBI Research finds that the competition in the global herpes therapeutics market is strong, with the presence of four primary marketed drugs and many generic brands. The total viral therapeutics market is forecast to grow at a high rate until 2018. The emergence of novel therapies concentrating on increasing drug safety and increasing patient awareness and compliance are major factors that will contribute to the growth of this market. Since the market is genericized, there are numerous small tier companies manufacturing therapeutic drugs. However, the tier one manufacturers such as GlaxoSmithKline and Novartis will continue to dominate the market due to their extensive marketing and licensing strategies.
The herpes therapeutics market (herpes simplex and herpes zoster) was valued at $3.6 billion in 2010. The market grew at a CAGR of 14.2%, from $1.6 billion in 2004 to $3.6 billion in 2010. The primary objectives of the available therapies are the suppression and treatment of the symptoms of the disease. Drugs such as antivirals, analgesics.
GBI Research finds that the global herpes market is an attractive one. The market is expected to witness growth during the forecast period and to provide good opportunities for investors. The high growth that is expected in the market is attributed to a number of factors, including increasing awareness about herpes infections, and a growth in the diseased population. Many promising therapies, especially for Cytomegalovirus (CMV) infections, are expected to be launched during the forecast period. The market is currently generic in nature, with few first in class molecules, and the current therapies provide only symptomatic treatment of infections - infections, once treated, can recur. The market, therefore, contains a significant unmet need, which needs to be resolved.
Global Herpes Market is Forecast to Grow at CAGR of 10.1%, Due to Growth in Diseased Population
The value of the global herpes market is estimated to have been approximately $4.2 billion in 2010, and is projected to grow at a CAGR of 10.1% until reaching $9.1 billion by 2018. The market has limited scope for growth due to the presence of generic products and a lack of innovation in the pipeline products. The current treatment options serve the market needs, providing symptomatic treatment for herpes simplex and herpes zoster infections. There is current unmet need in the market for safe therapeutics, particularly for CMV infections. There are nine molecules in Phase III of clinical development, being developed for various herpes infections. The diseased population is expected to grow to approximately 158.6 million by 2018. The growth in immunosuppressed patients and transplant recipients will be the driver for this market. The herpes market has strong competition from generics.
Herpes Therapeutics Market is Forecast to Grow at a CAGR of 11.2%, Despite Weak Pipeline and Presence of Generics in the Market
The herpes therapeutics market (herpes simplex and herpes zoster infections market) is forecast to grow at a CAGR of 11.2% during the forecast period 2010-2018. The herpes therapeutics market has low unmet needs in terms of both efficacy and safety - the efficacy of the present therapeutics ranges from moderate to strong, with drugs such as Zovirax having significantly strong efficacy profiles. Therapeutic interventions for herpes simplex are limited to oral formulations. The herpes therapeutics market is generic and there are many brands available with low prices. There are few first-in-class molecules present in the herpes therapeutics pipeline. Of these few, BA-021 is filed in the US for herpes simplex infections and it is expected to launch soon. In 2010, the diseased population of herpes simplex was estimated to be 120.3 million. The major driver of the market is the increase in diseased population, while a lack of awareness and social stigma are considered to be restraints on the herpes therapeutics market. Zostavax is the only vaccine approved in the US for the prophylactic treatment of herpes zoster infections. The launch of vaccine candidates such as GlaxoSmithKline Biologicals' GSK1437173A vaccine and V212 from Merck & Co. is expected in the coming years for herpes zoster infections
Launch of New Treatment Options Can Satisfy Current Unmet Needs of CMV Infections Market
The global CMV infection market was valued at $0.7 billion in 2010. The emergence of novel therapies, which concentrate on increased safety, has combined with increasing patient awareness and compliance to stimulate the growth of this market. The majority of pipeline products are biologics, contrary to the current marketed products, which are small molecules. The growth of the market can be attributed to the increasing number of AIDS/HIV patients, and Hematopoietic Stem Cell Transplantation (HSCT) and solid organ transplant recipients, all of which experience immunosuppression. The toxicity of the antiviral drugs used for the treatment of congenital CMV represents an unmet need in the existing treatment. Due to the long treatment duration of the antiviral drugs currently used in for the pre-emptive or prophylactic treatment of CMV infections in HSCT or SOT recipients, the chances of developing drug-related toxicity from that treatment is relatively high. Patients' development of resistance to current antiviral therapy is also a limitation for growth of this market. New treatment options, which are currently in Phase III, such as TransVax and Adoptive Cellular Therapy, are expected to satisfy the unmet needs of the market.